Search research articles
Contact Us
Filters
Showing results (231-240 of 343) with videos related to
Page
of 35
Sort By:
Blood
|
October 28, 2018
Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients
Romanos Sklavenitis-Pistofidis, Marzia Capelletti, Chia-Jen Liu, et al.
Blood
|
May 27, 2014
Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia
Steven P Treon, Christina K Tripsas, Kirsten Meid, et al.
Blood Advances
|
July 17, 2025
Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenström macroglobulinemia
Jorge J Castillo, Alberto Guijosa, John N Allan, et al.
British Journal of Haematology
|
March 13, 2021
Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenström macroglobulinaemia
Joshua N Gustine, Lian Xu, Guang Yang, et al.
Blood Advances
|
October 21, 2020
Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia
Jorge J Castillo, Edward N Libby, Stephen M Ansell, et al.
JCO Global Oncology
|
November 9, 2022
Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System
María Elena Cabrera, Camila Peña, Pilar Leon, et al.
Leukemia & Lymphoma
|
September 29, 2021
An international, multicenter, retrospective study on the positive impact of cutaneous involvement on the clinical outcome of adult T-cell leukemia/lymphoma
Luis Malpica, Denisse Castro, Daniel J Enriquez, et al.
British Journal of Haematology
|
December 22, 2015
Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study
Jorge J Castillo, Shirley D'Sa, Michael P Lunn, et al.
American Journal of Hematology
|
January 17, 2020
CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors
Jorge J Castillo, Joshua N Gustine, Kirsten Meid, et al.
British Journal of Haematology
|
November 19, 2025
Repurposing pacritinib to target MYD88-mutated Waldenström macroglobulinaemia
Shirong Liu, Amanda Kofides, Xia Liu, et al.
Page
of 35
Search research articles
Search
Showing results (231-240 of 343) with videos related to
Sort By:
Page
of 35
Blood
|
October 28, 2018
Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients
Romanos Sklavenitis-Pistofidis, Marzia Capelletti, Chia-Jen Liu, et al.
Blood
|
May 27, 2014
Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia
Steven P Treon, Christina K Tripsas, Kirsten Meid, et al.
Blood Advances
|
July 17, 2025
Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenström macroglobulinemia
Jorge J Castillo, Alberto Guijosa, John N Allan, et al.
British Journal of Haematology
|
March 13, 2021
Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenström macroglobulinaemia
Joshua N Gustine, Lian Xu, Guang Yang, et al.
Blood Advances
|
October 21, 2020
Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia
Jorge J Castillo, Edward N Libby, Stephen M Ansell, et al.
JCO Global Oncology
|
November 9, 2022
Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System
María Elena Cabrera, Camila Peña, Pilar Leon, et al.
Leukemia & Lymphoma
|
September 29, 2021
An international, multicenter, retrospective study on the positive impact of cutaneous involvement on the clinical outcome of adult T-cell leukemia/lymphoma
Luis Malpica, Denisse Castro, Daniel J Enriquez, et al.
British Journal of Haematology
|
December 22, 2015
Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study
Jorge J Castillo, Shirley D'Sa, Michael P Lunn, et al.
American Journal of Hematology
|
January 17, 2020
CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors
Jorge J Castillo, Joshua N Gustine, Kirsten Meid, et al.
British Journal of Haematology
|
November 19, 2025
Repurposing pacritinib to target MYD88-mutated Waldenström macroglobulinaemia
Shirong Liu, Amanda Kofides, Xia Liu, et al.
Page
of 35